Goldman Sachs Group, Inc. (The) started coverage on shares of Incyte Corporation (NASDAQ:INCY) in a report issued on Friday, MarketBeat reports. The firm issued a buy rating and a $160.00 price target on the biopharmaceutical company’s stock.

INCY has been the topic of several other research reports. BMO Capital Markets reaffirmed an outperform rating and issued a $163.00 price target (down previously from $172.00) on shares of Incyte Corporation in a research note on Monday, September 11th. Jefferies Group LLC reaffirmed a buy rating and issued a $148.00 price target on shares of Incyte Corporation in a research note on Thursday, July 27th. Oppenheimer Holdings, Inc. reaffirmed a hold rating and issued a $135.00 price target on shares of Incyte Corporation in a research note on Sunday, September 10th. Credit Suisse Group set a $152.00 price target on shares of Incyte Corporation and gave the stock a buy rating in a research note on Sunday, July 16th. Finally, Evercore ISI began coverage on shares of Incyte Corporation in a research note on Wednesday, August 16th. They issued an in-line rating and a $135.00 price target on the stock. Seven investment analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the stock. The company currently has a consensus rating of Buy and a consensus target price of $144.84.

Incyte Corporation (NASDAQ INCY) opened at 114.70 on Friday. Incyte Corporation has a 12 month low of $83.01 and a 12 month high of $153.15. The stock’s market cap is $23.59 billion. The company’s 50 day moving average is $121.38 and its 200 day moving average is $127.20.

Incyte Corporation (NASDAQ:INCY) last posted its quarterly earnings results on Tuesday, August 1st. The biopharmaceutical company reported ($0.06) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.05) by ($0.01). The company had revenue of $326.40 million during the quarter, compared to analysts’ expectations of $318.45 million. Incyte Corporation had a negative return on equity of 21.57% and a negative net margin of 11.77%. The company’s quarterly revenue was up 32.5% on a year-over-year basis. During the same period in the prior year, the business earned $0.18 EPS. On average, analysts anticipate that Incyte Corporation will post ($0.83) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Incyte Corporation (INCY) Earns Buy Rating from Analysts at Goldman Sachs Group, Inc. (The)” was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece of content on another site, it was illegally copied and republished in violation of US and international trademark and copyright laws. The original version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/10/09/incyte-corporation-incy-earns-buy-rating-from-analysts-at-goldman-sachs-group-inc-the.html.

In other Incyte Corporation news, EVP Paula J. Swain sold 20,000 shares of the firm’s stock in a transaction dated Thursday, August 31st. The shares were sold at an average price of $140.00, for a total transaction of $2,800,000.00. Following the transaction, the executive vice president now owns 55,067 shares of the company’s stock, valued at approximately $7,709,380. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Paul Trower sold 3,000 shares of the firm’s stock in a transaction dated Tuesday, September 5th. The shares were sold at an average price of $138.41, for a total transaction of $415,230.00. Following the transaction, the insider now directly owns 14,853 shares in the company, valued at approximately $2,055,803.73. The disclosure for this sale can be found here. Insiders have sold a total of 109,452 shares of company stock worth $13,707,134 in the last three months. Insiders own 17.70% of the company’s stock.

Institutional investors have recently modified their holdings of the company. D. Scott Neal Inc. purchased a new position in shares of Incyte Corporation in the 2nd quarter worth approximately $103,000. Tower Research Capital LLC TRC purchased a new position in shares of Incyte Corporation in the 1st quarter worth approximately $105,000. Cornerstone Advisors Inc. grew its position in shares of Incyte Corporation by 19.6% in the 2nd quarter. Cornerstone Advisors Inc. now owns 884 shares of the biopharmaceutical company’s stock worth $111,000 after buying an additional 145 shares during the last quarter. Exane Asset Management purchased a new position in shares of Incyte Corporation in the 2nd quarter worth approximately $126,000. Finally, Seven Eight Capital LP purchased a new position in shares of Incyte Corporation in the 2nd quarter worth approximately $129,000. 88.91% of the stock is currently owned by hedge funds and other institutional investors.

About Incyte Corporation

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).

Analyst Recommendations for Incyte Corporation (NASDAQ:INCY)

Receive News & Stock Ratings for Incyte Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte Corporation and related stocks with our FREE daily email newsletter.